BeyondSpring (BYSI) Upgraded to Buy by Zacks Investment Research

Zacks Investment Research upgraded shares of BeyondSpring (NASDAQ:BYSI) from a hold rating to a buy rating in a research report sent to investors on Thursday morning. They currently have $30.00 price target on the stock.

According to Zacks, “BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company’s lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. “

How to Become a New Pot Stock Millionaire

Other equities research analysts also recently issued reports about the stock. Maxim Group set a $52.00 price target on shares of BeyondSpring and gave the stock a buy rating in a research note on Tuesday, April 3rd. HC Wainwright set a $60.00 price target on shares of BeyondSpring and gave the stock a buy rating in a research note on Tuesday, April 3rd. Five equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and a consensus target price of $49.60.

Shares of NASDAQ BYSI opened at $27.00 on Thursday. BeyondSpring has a 1-year low of $19.55 and a 1-year high of $48.49.

BeyondSpring (NASDAQ:BYSI) last posted its quarterly earnings results on Tuesday, April 3rd. The company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.06). analysts expect that BeyondSpring will post -2.8 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/beyondspring-bysi-upgraded-to-buy-by-zacks-investment-research.html.

BeyondSpring Company Profile

BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.

Get a free copy of the Zacks research report on BeyondSpring (BYSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply